Biocodex’s Diacomit (stiripentol) Receives FDA Approval for Seizures Associated with Dravet Syndrome (DS) in Patients Aged 2 Years or Older

 Biocodex’s Diacomit (stiripentol) Receives FDA Approval for Seizures Associated with Dravet Syndrome (DS) in Patients Aged 2 Years or Older

Biocodex’s Diacomit (stiripentol) Receives FDA Approval for Seizures Associated with Dravet Syndrome (DS) in Patients Aged 2 Years or Older

Shots:

  • The approval is based on two study STICLO France and STICLO Italy assessing Diacomit vs PBO in patients with Dravet Syndrome aged 2 years of age and older taking clobazam
  • STICLO France and STICLO Italy study results: responder rate (71%, 67% vs 5%, 9.1%)
  • Diacomit 250mg & 500mg (stiripentol) is an anti-convulsant drug, approved as an adjunctive treatment with clobazam and valproate DS in 27 countries including EU, Canada, Japan in Jan 2007, Dec 2012, Sept 2012 respectively

Click here to read full press release/ article | Ref: PRNewsWire | Image: Twitter

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post